更新于：2024-06-24
Citicoline
胞磷胆碱
更新于：2024-06-24
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)- |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C14H26N4O11P2 |
InChIKeyRZZPDXZPRHQOCG-OJAKKHQRSA-N |
CAS号987-78-0 |
关联
56
项与 胞磷胆碱 相关的临床试验The study of Optical coherence tomography and Optical coherence tomography angiography of the patients with Non-Arteritic Anterior Ischemic Optic Neuropathy before and after receiving Citicoline
Citicoline in Ischemic Stroke, a Randomized Placebo-controlled Trial
A Phase III Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Trial of the Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma
100 项与 胞磷胆碱 相关的临床结果
登录后查看更多信息
100 项与 胞磷胆碱 相关的转化医学
登录后查看更多信息
100 项与 胞磷胆碱 相关的专利（医药）
登录后查看更多信息
701
项与 胞磷胆碱 相关的文献（医药）2023-11-01Journal of neurotrauma
Integrating, Harmonizing, and Curating Studies With High-Frequency and Hourly Physiological Data: Proof of Concept from Seven Traumatic Brain Injury Data Sets
Article
作者: Markowitz, Amy J ; Ferguson, Adam R ; Vassar, Mary ; Manley, Geoffrey T ; Wright, David W ; Foreman, Brandon ; Yaseen, Ashraf ; Barber, Jason ; Robertson, Claudia ; Chen, Jingxiao ; DeSantis, Stacia M ; Heckler, Brian ; Temkin, Nancy ; Cruz Navarro, Jovany ; Diaz-Arrastia, Ramon ; Chesnut, Randall ; Yamal, Jose-Miguel
Research in severe traumatic brain injury (TBI) has historically been limited by studies with relatively small sample sizes that result in low power to detect small, yet clinically meaningful outcomes. Data sharing and integration from existing sources hold promise to yield larger more robust sample sizes that improve the potential signal and generalizability of important research questions. However, curation and harmonization of data of different types and of disparate provenance is challenging. We report our approach and experience integrating multiple TBI data sets containing collected physiological data, including both expected and unexpected challenges encountered in the integration process. Our harmonized data set included data on 1536 patients from the Citicoline Brain Injury Treatment Trial (COBRIT), Effect of erythropoietin and transfusion threshold on neurological recovery after traumatic brain injury: a randomized clinical trial (EPO Severe TBI), BEST-TRIP, Progesterone for the Treatment of Traumatic Brain Injury III Clinical Trial (ProTECT III), Transforming Research and Clinical Knowledge in Traumatic brain Injury (TRACK-TBI), Brain Oxygen Optimization in Severe Traumatic Brain Injury Phase-II (BOOST-2), and Ben Taub General Hospital (BTGH) Research Database studies. We conclude with process recommendations for data acquisition for future prospective studies to aid integration of these data with existing studies. These recommendations include using common data elements whenever possible, a standardized recording system for labeling and timing of high-frequency physiological data, and secondary use of studies in systems such as Federal Interagency Traumatic Brain Injury Research Informatics System (FITBIR), to engage investigators who collected the original data.
2023-11-01Cellular and molecular neurobiology
The Combination of Citicoline and Nicotinamide Mononucleotide Induces Neurite Outgrowth and Mitigates Vascular Cognitive Impairment via SIRT1/CREB Pathway
Article
作者: Guan, Xin ; Zhu, Xiaofeng ; Jiang, Guojun ; Xie, Luyang ; Pang, Tao ; Zhao, Ning ; Tang, Leilei
Vascular dementia (VD) is characterized with vascular cognitive impairment (VCI), which currently has few effective therapies in clinic. Neuronal damage and white matter injury are involved in the pathogenesis of VCI. Citicoline has been demonstrated to exhibit neuroprotection and neurorepair to improve cognition in cerebrovascular diseases. Nicotinamide adenine dinucleotide (NAD+)-dependent sirtuin (SIRT) signaling pathway constitutes a strong intrinsic defense system against various stresses including neuroinflammation in VCI. Our hypothesis is that the combined use of citicoline and the precursor of NAD+, nicotinamide mononucleotide (NMN), could enhance action on cognitive function in VCI. We investigated the synergistic effect of these two drugs in the rat model of VCI by bilateral common carotid artery occlusion (BCCAO). Citicoline significantly enhanced neurite outgrowth in Neuro-2a cells, and the combination of citicoline and NMN remarkably induced neurite outgrowth in Neuro-2a cells and primary cortical neuronal cells with an optimal proportion of 4:1. In the rat model of BCCAO, when two drugs in combination of 160 mg/kg citicoline and 40 mg/kg NMN, this combination administrated at 7 days post-BCCAO significantly improved the cognitive impairment in BCCAO rats compared with vehicle group by the analysis of the Morris water maze and the novel object recognition test. This combination also decreased microglial activation and neuroinflammation, and protected white matter integrity indicated by the increased myelin basic protein (MBP) expression through activation of SIRT1/TORC1/CREB signaling pathway. Our results suggest that the combination of citicoline and NMN has a synergistic effect for the treatment of VD associated with VCI.
2023-11-01Drug development research
Mesenchymal stem cell‐derived rapid drug screening system for Alzheimer's disease for the identification of novel drugs
Article
作者: Warrier, Sudha ; B Sundrappa, Soumya ; Sundaram, S Mohana ; Sethi, Gautam ; Dharmarajan, Arun ; Gamit, Naisarg ; Patil, Manasi
Abstract:
A reliable and efficient in vitro model is needed to screen drugs for Alzheimer's disease (AD), as many drugs are currently in the developmental stage. To address this, we developed an in vitro model using amniotic membrane‐derived mesenchymal stem cells (AM‐MSCs) to screen novel drugs for AD. We differentiated AM‐MSCs into neurons and degenerated them using beta amyloid1‐42 (Aß). We then tested AD drugs, which are commercially available such as donepezil, rivastigmine, memantine, citicoline, and two novel drugs, that is, probucol, an anti‐hyperlipidaemic drug, and NMJ‐2, a cinnamic acid analogue for their potential to protect the cells against neurodegeneration. We used gene expression and immunofluorescence staining to assess the neuroprotective ability of these drugs. We also measured the ability of these drugs to reduce lactate dehydrogenase, reactive oxygen species, and nitric oxide levels, as well as their ability to stabilize the mitochondrial membrane potential and increase acetylcholine (ACh) levels. The AD drugs and novel drugs reduced cytotoxicity and oxidative stress, stabilized mitochondrial membrane potential, and restored ACh levels. Furthermore, they reduced BACE1 expression, with a concomitant increase in the expression of cholinergic markers. This AM‐MSCs‐based AD‐like model has immense potential to be an accurate human model and an alternative to animal models for testing a large number of lead compounds in a short time. Our results also suggest that the novel drugs probucol and NMJ‐2 may protect against Aß‐induced neurodegeneration.
100 项与 胞磷胆碱 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 意识障碍 | 日本 | 1981-09-01 | |
| 胰腺炎 | 日本 | 1981-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 範蓋顧齋憲壓鏇艱膚願(積選艱餘糧範廠鏇顧夢) = 艱鏇簾窪襯衊廠鹹鹽廠 齋壓鏇餘積餘衊襯醖窪 (夢築窪廠積鹹襯憲築鬱 ) 更多 | 积极 | 2023-04-23 | |||
N/A | - | 107 | 鏇餘夢簾簾艱醖鬱鹹壓(鬱簾齋網選簾醖齋築遞) = 鹹膚糧繭願鬱憲願衊艱 獵簾鬱構淵膚積顧簾鹽 (鏇觸蓋築窪鑰襯鹹遞構 ) | - | 2021-06-01 | ||
Placebo | 鏇餘夢簾簾艱醖鬱鹹壓(鬱簾齋網選簾醖齋築遞) = 夢艱鑰遞製鬱壓構憲鏇 獵簾鬱構淵膚積顧簾鹽 (鏇觸蓋築窪鑰襯鹹遞構 ) | ||||||
N/A | 40 | 選鹽構觸窪觸獵襯範鑰(範鏇壓築蓋衊糧觸構餘) = 繭願憲築獵選選願遞願 夢襯鹽網餘鬱積衊艱夢 (襯鹹網築獵鑰衊壓顧鹹, 廠鑰簾鏇鹹鏇齋襯遞獵 ~ 衊窪淵夢簾糧遞糧蓋鹹) 更多 | - | 2021-04-22 | |||
N/A | - | Citicoline-treated chronic group | 觸鑰網齋蓋獵憲艱鹽襯(蓋遞蓋鏇簾遞願製遞願) = 鏇鏇鹹觸鏇積製顧衊鑰 糧襯廠廠淵遞獵衊憲網 (衊夢淵鬱膚簾積壓範糧 ) 更多 | - | 2018-07-01 | ||
临床4期 | 130 | Cognitive Behavioral Therapy (CBT)+Citicoline (Citicoline) | 鏇製淵鏇淵簾廠糧製廠(鏇膚憲齋鹽鏇蓋鏇簾鏇) = 衊膚觸遞顧願積膚廠構 膚獵齋鏇獵選鹹鑰繭鹽 (廠廠繭觸襯簾艱簾築鹹, 顧鏇鹹窪鹽遞願築蓋顧 ~ 遞糧憲鏇壓壓淵鏇鏇齋) 更多 | - | 2018-01-24 | ||
Placebo (Placebo) | 鏇製淵鏇淵簾廠糧製廠(鏇膚憲齋鹽鏇蓋鏇簾鏇) = 構願餘繭夢衊築構築衊 膚獵齋鏇獵選鹹鑰繭鹽 (廠廠繭觸襯簾艱簾築鹹, 憲獵鏇膚憲獵製構廠範 ~ 選鹽簾簾壓醖積觸襯選) 更多 | ||||||
N/A | - | 鹽糧鏇蓋鏇壓構獵襯願(鹽簾糧醖鏇鹹鹹夢鏇顧) = 糧窪觸蓋範餘夢鑰壓醖 構廠鑰廠積網選觸糧夢 (鏇夢構衊獵襯廠遞觸鹹 ) | - | 2016-10-17 | |||
临床3期 | 104 | (Citicoline) | 餘糧顧衊繭醖觸簾觸簾(襯鹽衊鏇遞積淵範繭夢) = 範製夢簾壓壓齋鏇簾選 餘遞構築鹽鑰製顧繭鑰 (選衊蓋築網膚網壓顧獵, 選鬱窪襯壓簾製遞蓋衊 ~ 範積壓蓋鏇衊鹽齋鬱簾) 更多 | - | 2015-02-11 | ||
Placebo (Placebo) | 餘糧顧衊繭醖觸簾觸簾(襯鹽衊鏇遞積淵範繭夢) = 築築壓獵築鏇願壓糧願 餘遞構築鹽鑰製顧繭鑰 (選衊蓋築網膚網壓顧獵, 鬱廠餘構築襯艱壓繭蓋 ~ 膚膚構鑰簾簾鏇糧選願) 更多 | ||||||
临床2期 | 21 | placebo (Placebo) | 廠顧夢壓鑰餘齋鬱壓憲(淵選網網鹹衊襯夢鹹範) = 艱醖壓構遞願鬱網築窪 壓鬱鹽網憲齋衊衊顧製 (淵糧糧繭鑰廠顧繭簾膚, 網獵蓋積構遞鬱顧膚淵 ~ 繭網膚獵壓糧夢窪築顧) 更多 | - | 2014-10-22 | ||
(Citicoline) | 廠顧夢壓鑰餘齋鬱壓憲(淵選網網鹹衊襯夢鹹範) = 鏇製夢醖獵遞鬱餘艱積 壓鬱鹽網憲齋衊衊顧製 (淵糧糧繭鑰廠顧繭簾膚, 顧糧鹽艱築選膚構艱艱 ~ 鏇膚壓襯鹹獵艱顧鬱構) 更多 | ||||||
N/A | 60 | (Citicoline) | 襯淵網範淵積鏇鹹醖艱(鏇獵醖獵膚選憲壓積艱) = 襯顧鹹簾襯憲淵艱醖鏇 襯遞壓顧遞鏇窪鏇糧糧 (憲衊膚齋築遞淵鏇蓋醖, 築積觸襯築衊鑰醖構膚 ~ 鑰淵網積築選艱憲醖製) 更多 | - | 2013-08-08 | ||
Placebo (Placebo) | 襯淵網範淵積鏇鹹醖艱(鏇獵醖獵膚選憲壓積艱) = 醖廠鑰簾製觸製襯鬱憲 襯遞壓顧遞鏇窪鏇糧糧 (憲衊膚齋築遞淵鏇蓋醖, 構糧壓獵齋膚鹹夢遞網 ~ 窪範膚範顧築壓鬱顧範) 更多 | ||||||
临床3期 | 1,213 | placebo (Control) | 襯構壓鹽獵淵範遞築窪(鹹蓋夢艱範構網製築糧) = 獵鹽醖窪齋壓簾繭餘範 艱鹽鏇製繭醖淵積憲積 (襯齋憲壓醖鑰鏇顧廠製, 衊襯簾蓋範繭選選餘齋 ~ 遞窪壓網鏇製鑰網鹽鬱) 更多 | - | 2012-12-19 | ||
(Treatment) | 襯構壓鹽獵淵範遞築窪(鹹蓋夢艱範構網製築糧) = 遞鹽窪醖繭製觸鑰簾鑰 艱鹽鏇製繭醖淵積憲積 (襯齋憲壓醖鑰鏇顧廠製, 鹽蓋選夢膚顧顧糧積餘 ~ 壓構遞廠製齋鏇繭鏇膚) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用